头孢美唑和头孢西丁对产与非产超广谱β内酰胺酶菌株体外抗菌活性比较

In vitro activity of cefmetazole against extended-spectrum beta-lactamases producing and non-producing strains: a comparison with cefoxitin

目的测定头孢美唑和头孢西丁对产ESBLs菌株的体外抗菌活性,并与非产ESBLs菌株的体外抗菌活性相比较。方法收集2004年1—12月华西医院各临床科室分离出的大肠埃希菌和肺炎克雷伯菌520株,采用Kirby-Bauer琼脂扩散法进行体外药敏试验并用表型确证试验检测ESBLs。结果筛选出产ESBLs菌226株,产酶菌检出率为43.5%,其中323株大肠埃希菌的ESBLs检出率为45.8%,197株肺炎克雷伯菌的ESBLs检出率为39.6%。头孢美唑对我院产ESBLs菌株体外抗菌活性优于头孢西丁。结论头霉素类抗生素可作为治疗产ESBLs菌株引起的感染的可选药物,但仍应参考药敏试验结果。我院分离的产ESBLs大肠埃希菌和肺炎克雷伯菌对头孢美唑的敏感性略优于头孢西丁。

ObjectiveTo determine the in vitro antimicrobial activity of cefmetazole and cefoxitin against extended-spectrum beta-lactamases(ESBLs) producing and non-producing strains.MethodsA total of 520 strains of K.pneumoniae and E.coli were isolated from January 2004 to December 2004.Phenotypic confirmatory test was used to detect ESBLs.Kirby-Bauer agar diffusion method was used for susceptibility testing.ResultsOverall,226 ESBLs-producing strains were detected.The positive rate of ESBLs was 43.5%,specifically 45.8% among E.coli isolates and 39.6% among K.pneumoniae.In vitro antimicrobial activity of cefmetazole against ESBLs producing strains was higher than that of cefoxitin in West China Hospital.ConclusionsCephamycins can be the alternative treatment for ESBLs producing strains.The in vitro antimicrobial activity of cefmetazole against ESBLs producing strains is higher than that of cefoxitin in West China Hospital.